We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
SYK Q3 Earnings: Can Recovery Momentum Offset Operational Headwinds?
Read MoreHide Full Article
Key Takeaways
SYK's Q3 earnings are expected to rise 11.6% to $3.56 per share, with revenues growing 8.6% to $6.58 billion.
Strong hospital equipment demand, elevated backlog and Mako robotic adoption could support SYK's Q3 growth.
Cybersecurity recovery, peripheral vascular supply disruptions and rising costs may pressure SYK's margins.
Stryker (SYK - Free Report) is scheduled to report third-quarter 2026 results on Oct. 29, after market close. The quarterly numbers are likely to reflect continued recovery from its cybersecurity disruption, strong demand for hospital capital equipment and progress in restoring production. However, supply-chain challenges, uneven business recovery and elevated execution requirements remain important concerns for investors.
Investors will closely monitor revenue performance, production recovery, peripheral vascular trends and margin developments during the company's third-quarter earnings call.
Over the three-month period beginning June 30, 2026, Stryker shares declined 12.5%, underperforming the Zacks Medical-Products and the S&P 500 Index, which advanced 1.4% and 1.6%, respectively.
Image Source: Zacks Investment Research
Earnings Surprise History
SYK beat on earnings in three of the trailing four quarters and missed in one, delivering an average negative surprise of 0.73%.
Image Source: Zacks Investment Research
Consensus Estimates
The Zacks Consensus Estimate for third-quarter earnings is pinned at $3.56 per share, indicating an improvement of 11.6%. The earnings estimate has remained unchanged over the past seven days. The consensus estimate for revenues is pinned at $6.58 billion, suggesting 8.6% year-over-year growth.
Quarterly Drivers and Challenges
Capital Equipment Demand and Production Recovery: During the second-quarter earnings call, management expressed confidence in second-half growth, supported by robust hospital capital-equipment demand and a strong order backlog. Production ramp-up following the cybersecurity incident remained critical to fulfilling orders. Successful execution should have supported revenue realization in the third quarter, although manufacturing constraints might have limited the pace of recovery.
Robotics and Product Innovation: Stryker reported strong adoption of its Mako robotic-assisted surgery platform and positive early feedback on Mako RPS during the second quarter. New product launches across orthopedics, medical equipment and surgical technologies could enhance the company’s competitive position and support long-term growth. These favorable trends are also likely to have supported Mako sales in the third quarter.
Peripheral Vascular Disruption and Expenses: Management acknowledged that supply disruptions in the peripheral vascular business adversely affected sales during the second quarter. With the company expecting back orders to reach manageable levels by the end of the third quarter, investors will likely focus on this metric during the third-quarter earnings call to assess sales recovery. Cybersecurity remediation costs, manufacturing inefficiencies and raw-material pressures should have constrained profitability during the soon-to-be-reported quarter.
Our proven model does not conclusively predict an earnings beat for SYK this time around. The combination of a positive Earnings ESP and Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. However, that is not the case here, as you can see below.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate ($3.53 per share) and the Zacks Consensus Estimate, is -1.04%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank: SYK has a Zacks Rank #4 (Sell) at present.
Some stocks worth considering from the broader medical space are Glaukos (GKOS - Free Report) , Edward Lifesciences (EW - Free Report) and Globus Medical (GMED - Free Report) , each carrying a Zacks Rank #2 at present.
Glaukos reported second-quarter 2026 earnings per share of 14 cents, which beat the Zacks Consensus Estimate by 50.00%. Revenues of $186 million surpassed the Zacks Consensus Estimate by 24.1%.
Glaukos has an estimated earnings growth rate of 268.8% for 2027. GKOS’ earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 25.87%.
Edward Lifesciences reported second-quarter 2026 adjusted EPS of 78 cents, which beat the Zacks Consensus Estimate by 6.85%. Revenues of $1.74 billion surpassed the Zacks Consensus Estimate by 2.45%.
Edward Lifesciences has an estimated long-term earnings growth rate of 12.7%. EW’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 4.49%.
Globus Medical reported a second-quarter fiscal 2026 adjusted EPS of $1.34, which beat the Zacks Consensus Estimate by 19.6%. Revenues of $790 million missed the Zacks Consensus Estimate by 0.35%.
Globus Medical has an estimated long-term earnings growth rate of 12.4%. GMED’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 27.88%.
View the Zacks #1 Rank List
Image: Bigstock
SYK Q3 Earnings: Can Recovery Momentum Offset Operational Headwinds?
Key Takeaways
Stryker (SYK - Free Report) is scheduled to report third-quarter 2026 results on Oct. 29, after market close. The quarterly numbers are likely to reflect continued recovery from its cybersecurity disruption, strong demand for hospital capital equipment and progress in restoring production. However, supply-chain challenges, uneven business recovery and elevated execution requirements remain important concerns for investors.
Investors will closely monitor revenue performance, production recovery, peripheral vascular trends and margin developments during the company's third-quarter earnings call.
Over the three-month period beginning June 30, 2026, Stryker shares declined 12.5%, underperforming the Zacks Medical-Products and the S&P 500 Index, which advanced 1.4% and 1.6%, respectively.
Image Source: Zacks Investment Research
Earnings Surprise History
SYK beat on earnings in three of the trailing four quarters and missed in one, delivering an average negative surprise of 0.73%.
Image Source: Zacks Investment Research
Consensus Estimates
The Zacks Consensus Estimate for third-quarter earnings is pinned at $3.56 per share, indicating an improvement of 11.6%. The earnings estimate has remained unchanged over the past seven days. The consensus estimate for revenues is pinned at $6.58 billion, suggesting 8.6% year-over-year growth.
Quarterly Drivers and Challenges
Capital Equipment Demand and Production Recovery: During the second-quarter earnings call, management expressed confidence in second-half growth, supported by robust hospital capital-equipment demand and a strong order backlog. Production ramp-up following the cybersecurity incident remained critical to fulfilling orders. Successful execution should have supported revenue realization in the third quarter, although manufacturing constraints might have limited the pace of recovery.
Robotics and Product Innovation: Stryker reported strong adoption of its Mako robotic-assisted surgery platform and positive early feedback on Mako RPS during the second quarter. New product launches across orthopedics, medical equipment and surgical technologies could enhance the company’s competitive position and support long-term growth. These favorable trends are also likely to have supported Mako sales in the third quarter.
Peripheral Vascular Disruption and Expenses: Management acknowledged that supply disruptions in the peripheral vascular business adversely affected sales during the second quarter. With the company expecting back orders to reach manageable levels by the end of the third quarter, investors will likely focus on this metric during the third-quarter earnings call to assess sales recovery. Cybersecurity remediation costs, manufacturing inefficiencies and raw-material pressures should have constrained profitability during the soon-to-be-reported quarter.
Stryker Corporation Price and EPS Surprise
Stryker Corporation price-eps-surprise | Stryker Corporation Quote
What Our Model Unveils for Stryker Stock
Our proven model does not conclusively predict an earnings beat for SYK this time around. The combination of a positive Earnings ESP and Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. However, that is not the case here, as you can see below.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate ($3.53 per share) and the Zacks Consensus Estimate, is -1.04%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank: SYK has a Zacks Rank #4 (Sell) at present.
You can see the complete list of today’s Zacks #1 Rank stocks here.
Stocks to Consider
Some stocks worth considering from the broader medical space are Glaukos (GKOS - Free Report) , Edward Lifesciences (EW - Free Report) and Globus Medical (GMED - Free Report) , each carrying a Zacks Rank #2 at present.
Glaukos reported second-quarter 2026 earnings per share of 14 cents, which beat the Zacks Consensus Estimate by 50.00%. Revenues of $186 million surpassed the Zacks Consensus Estimate by 24.1%.
Glaukos has an estimated earnings growth rate of 268.8% for 2027. GKOS’ earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 25.87%.
Edward Lifesciences reported second-quarter 2026 adjusted EPS of 78 cents, which beat the Zacks Consensus Estimate by 6.85%. Revenues of $1.74 billion surpassed the Zacks Consensus Estimate by 2.45%.
Edward Lifesciences has an estimated long-term earnings growth rate of 12.7%. EW’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 4.49%.
Globus Medical reported a second-quarter fiscal 2026 adjusted EPS of $1.34, which beat the Zacks Consensus Estimate by 19.6%. Revenues of $790 million missed the Zacks Consensus Estimate by 0.35%.
Globus Medical has an estimated long-term earnings growth rate of 12.4%. GMED’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 27.88%.